Topical treatment of androgenetic alopecia with spironolactone

[Άκης]

Dill-Muller, D. and H. Zaun (1997). "Topical treatment of androgenetic alopecia with spironolactone." Journal of the European Academy of Dermatology and Venereology 9(Supplement 1): S31.

Abstract: Spironolactone, the aldosterone receptor antagonist, posses antiandrogenic effects by peripheral receptor inhibition and decrease of enzyme activity in the testosterone biosynthesis. We evaluated the effect of topical treatment with spironolactone (1% in Solutio Cordes®) on androgenic hair loss in women. The diagnosis has been based on clinical criteria (biparietal and/or central thinning of the scalp hair), more than 25% telogen hair in the frontal trichogram, regular endocrinology status and in some cases on punch biopsy. 60 female patients in three groups (Gr. 1: 24 patients with hemilateral monotherapy; Gr. 2: 20 patients with bilateral application and Gr. 3: 16 patients with combined systemic antiandrogen therapy) received topical treatment with 10 drops (gr. 1) spironolactone solution rsp. 20 drops (gr. 2 and 3) daily on the androgene dependent area of the scalp hair for minimum 6 months up to two years by now. Clinical status and trichogram had been controlled after 3 and 6 months. In case of objective response in group I, patients were advised in bilateral therapy. In group I 65% of the patients presented objective response and 40% of them - with early onset of spironolactone therapy - showed new hair growth. In group 2 the topical therapy results in improvement for 60% of the patients. Whereas in group 3 only 50% of the patients presented a decrease or stabilisation of their hair loss. Still an acceptable result regarding the previous long term systemic therapy without benefit. There were no changes in vital signs, e.g. hypotonia or hormonal disorders reported during the therapy.
Spironolactone is an effective topical treatment for the androgenetic alopecia in women.

 

[Άκης]

Απ: Topical treatment of androgenetic alopecia with spironolactone

Το παρακάτω είναι το πλήρες.
Abstract:
Spironolactone, the aldosterone receptor antagonist, posses antiandrogenic effects by peripheral receptor inhibition and decrease of enzyme activity in the testosterone biosynthesis.

[Spironolactone is an antiandrogen.]

We evaluated the effect of topical treatment with spironolactone (1% in Solutio Cordes®) on androgenic hair loss in women.

[We evaluated the effect of topically applied spironolactone (1% hydroalcoholic solution) in female androgenetic alopecia.]

The diagnosis has been based on clinical criteria (biparietal and/or central thinning of the scalp hair), more than 25% telogen hair in the frontal trichogram, regular endocrinology status and in some cases on punch biopsy.

[The diagnosis was based on the presence of thinning of the bitemporal or central (i.e., crown, vertex) regions of the scalp, more than 25% telogen phase hair as confirmed by a frontal trichogram, normal hormonal levels, and in some cases, a punch biopsy.]

60 female patients in three groups (Gr. 1: 24 patients with hemilateral monotherapy; Gr. 2: 20 patients with bilateral application and Gr. 3: 16 patients with combined systemic antiandrogen therapy) received topical treatment with 10 drops (gr. 1) spironolactone solution rsp. 20 drops (gr. 2 and 3) daily on the androgene dependent area of the scalp hair for minimum 6 months up to two years by now.

[60 female patients were recruited and divided into three groups. Group one consisted of 24 patients, and patients were instructed to apply 10 drops of spironolactone to the affected area on one side of the scalp (frontotemporal regions?). Group two included 20 patients, each of whom applied 10 drops to the affected area on both sides of the scalp. Group three consisted of 16 women, who in addition to receiving topical therapy as per group two, also received systemic antiandrogen treatment.

Condensed version:
Group one: 10 drops topically to one side of scalp (10 drops total)
Group two: 10 drops topically to each side of scalp (20 drops total)
Group three: same as group 2 *plus* systemic spironolactone.]

Clinical status and trichogram had been controlled after 3 and 6 months.

[Clinical status was assessed by trichogram at 3 and 6 months after initiation of therapy.]

In case of objective response in group I, patients were advised in bilateral therapy.

[If patients in group one appeared responsive to therapy (at either followup?), they were assigned the same treatment instructions as group two.]

In group I 65% of the patients presented objective response and 40% of them - with early onset of spironolactone therapy - showed new hair growth.

[65% of the patients in group one showed evidence of response; 40% showed new growth?]

In group 2 the topical therapy results in improvement for 60% of the patients.

[60% of patients in group two responded.]

Whereas in group 3 only 50% of the patients presented a decrease or stabilisation of their hair loss.

[Only 50% of group three (the women also receiving systemic spironolactone therapy) demonstrated a cessation or slowing of the progression of hair loss.]

Still an acceptable result regarding the previous long term systemic therapy without benefit. There were no changes in vital signs, e.g. hypotonia or hormonal disorders reported during the therapy. Spironolactone is an effective topical treatment for the androgenetic alopecia in women.

[More gibberish followed by positive remark about topical spironolactone treatment.]